Versavo Indications/Uses

Metastatic Colorectal Cancer mCRC): Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.
Locally recurrent or metastatic Breast Cancer (mBC): Bevacizumab in combination with standard cytotoxic chemotherapy is indicated for first-line treatment of patients with locally recurrent or metastatic breast cancer.
Bevacizumab in combination with taxanes, capecitabine or gemcitabine chemotherapies is indicated for the treatment of patients with metastatic breast cancer after failure of first-line cytotoxic chemotherapy.
Advanced, metastatic, or recurrent Non-Small Cell Lung Cancer (NSCLC): Bevacizumab in combination with platinum-based chemotherapy is indicated for first-line treatment of patients with unresectable metastatic or recurrent non-squamous non-small cell lung cancer.
Bevacizumab in combination with Erlotinib is indicated for first-line treatment of patients with unresectable advanced metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.
Advanced and/or metastatic Renal Cell Cancer (mRCC): Bevacizumab in combination with interferon alfa-2a is indicated for first-line treatment of patients with advanced and/or metastatic renal cell cancer.
Malignant Glioma (WHO Grade IV)-Glioblastoma: Bevacizumab in combination with radiotherapy and temozolomide is indicated for the treatment of adult patients with newly diagnosed glioblastoma.
Bevacizumab monotherapy or in combination with irinotecan is indicated for the treatment of patients with glioblastoma after relapse or disease progression.
Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer: Bevacizumab in combination with carboplatin and paclitaxel is indicated for the front-line treatment of advanced (FIGO stage III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Bevacizumab in combination with carboplatin and gemcitabine, or in combination with carboplatin and paclitaxel is indicated for the treatment of patients with first recurrent, platinum-sensitive, epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received chemotherapy in recurrent setting and not received prior Bevacizumab treatment.
Bevacizumab in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer, who received no more than two prior chemotherapy regimens.
Cervical Cancer: Bevacizumab in combination with paclitaxel and cisplatin, or paclitaxel and topotecan is indicated for the treatment of persistent, recurrent, or metastatic carcinoma of cervix.